Which statement about benzodiazepine taper strategies is true?

Study for the BIPC Substance Abuse and Disorders Exam. Challenge yourself with a variety of questions to enhance your knowledge and strengthen your preparation. Each question comes with hints and explanations to help you understand and retain crucial information.

Multiple Choice

Which statement about benzodiazepine taper strategies is true?

Explanation:
Tapering benzodiazepines should be done under medical supervision, often by converting to a longer-acting benzodiazepine and then gradually reducing the dose. This approach minimizes withdrawal symptoms, prevents rebound anxiety, insomnia, and autonomic symptoms, and reduces the risk of more serious complications like seizures. Longer-acting agents—such as diazepam or clonazepam—provide steadier blood levels, making the dose reductions smoother and easier to manage, while allowing healthcare providers to tailor the pace to the individual’s symptoms and comorbidities. Abrupt or very rapid stopping is unsafe because dependence means the body has adjusted to the drug; stopping quickly can provoke intense withdrawal that can be difficult to control and potentially dangerous. Simply having a patient agree to stop does not ensure safety or readiness for withdrawal. Switching to barbiturates is not a recommended strategy due to higher risks of overdose, dependence, and adverse effects, and because barbiturates have a narrower safety margin. So, tapering under medical supervision with a longer-acting benzodiazepine is the best-supported strategy.

Tapering benzodiazepines should be done under medical supervision, often by converting to a longer-acting benzodiazepine and then gradually reducing the dose. This approach minimizes withdrawal symptoms, prevents rebound anxiety, insomnia, and autonomic symptoms, and reduces the risk of more serious complications like seizures. Longer-acting agents—such as diazepam or clonazepam—provide steadier blood levels, making the dose reductions smoother and easier to manage, while allowing healthcare providers to tailor the pace to the individual’s symptoms and comorbidities.

Abrupt or very rapid stopping is unsafe because dependence means the body has adjusted to the drug; stopping quickly can provoke intense withdrawal that can be difficult to control and potentially dangerous. Simply having a patient agree to stop does not ensure safety or readiness for withdrawal. Switching to barbiturates is not a recommended strategy due to higher risks of overdose, dependence, and adverse effects, and because barbiturates have a narrower safety margin.

So, tapering under medical supervision with a longer-acting benzodiazepine is the best-supported strategy.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy